is being presented by Herb Cohen, Senior Managing Partner, with Performance Connections International, Inc. and airs on Wednesday, September 29th, 2010. For more details or to register for this event, please visit our site at www.fxconferences.com
Successful scientists, engineers and IT professionals realize the importance of developing ongoing and productive “win-win” relationships with others outside their own department. Especially when resources are stretched, influencing and negotiating with coworkers in different areas of the company to gain their time and commitment to meet your needs is critical to the success of your business.
When your goal is to influence coworkers, you often face unique challenges and issues. While you and your coworkers all support the greater needs of the company, understanding each other’s individual and departmental issues is important in getting results. This isn’t always simple to do, and, in fact, can become even more complicated when you must make your case to a group, rather than to an individual.
This audio conference discusses how the genetic wiring of most technical professionals is different than other occupational groups. Speaker Herb Cohen explains how to resolve issues in a positive way that maintains the internal customer relationship, and shares top strategies that are mutually beneficial to everyone and that will benefit you and your company in both the short and long term.
Tuesday, August 31, 2010
Friday, August 27, 2010
Comparative Effectiveness Research: Threat or Opportunity?
is being presented by Dr. Edward E. Berger, Principal and Founder, of Larchmont Strategic Advisors and airs on Wednesday, September 22nd, 2010. For more details or to register, please visit our site at www.fxconferences.com
Comparative effectiveness research (CER), a prominent component of legislative and regulatory efforts to rationalize the use of health care resources, improve outcomes and constrain the explosive growth of health care spending, is widely perceived as a financial threat by medical technology and pharmaceutical companies. During the current healthcare reform debate, industry has supported stringent limits on payers’ use of CER results in an effort to minimize its impact. But CER also has the potential to define new market opportunities for existing technologies and to open new pathways for the introduction of innovative diagnostics and therapeutics. Opposition to CER initiatives may foreclose significant growth potential for industry.
This presentation explores how CER is likely to be implemented, analyzes the nature of the threat posed by CER to the commercial status quo, and evaluates the opportunities that a robust implementation of a CER program would create.
Comparative effectiveness research (CER), a prominent component of legislative and regulatory efforts to rationalize the use of health care resources, improve outcomes and constrain the explosive growth of health care spending, is widely perceived as a financial threat by medical technology and pharmaceutical companies. During the current healthcare reform debate, industry has supported stringent limits on payers’ use of CER results in an effort to minimize its impact. But CER also has the potential to define new market opportunities for existing technologies and to open new pathways for the introduction of innovative diagnostics and therapeutics. Opposition to CER initiatives may foreclose significant growth potential for industry.
This presentation explores how CER is likely to be implemented, analyzes the nature of the threat posed by CER to the commercial status quo, and evaluates the opportunities that a robust implementation of a CER program would create.
Wednesday, August 25, 2010
Sustainability: The Business Case and Beyond
is being presented by Federico Fische, Renewable Energy Consultant and airs on Wednesday, November 17th, 2010. For more details or to register, please visit our site at www.fxconferences.com
We are constantly being bombarded by terms like green, sustainable, and social responsibility. Corporations, state and municipal officials and consumers are being urged to reduce their “carbon footprint” and to become more “green” and “sustainable.”
Both the public and private sector are engaged in parallel decision-making processes addressing the environment and the sustainability of the society as a whole. These decisions will affect the way corporations and government work, and the shape of the business environment. Changes in consumer behavior will affect how corporations and government will deliver their goods and services. The goal is to raise the level of debate on climate change and the environment, and promote an understanding of what government officials at the federal, state and municipal level are trying to say and do. This audio conference looks at the concepts behind the trendy buzzwords, and examines both the social and business case for 'going green'.
We are constantly being bombarded by terms like green, sustainable, and social responsibility. Corporations, state and municipal officials and consumers are being urged to reduce their “carbon footprint” and to become more “green” and “sustainable.”
Both the public and private sector are engaged in parallel decision-making processes addressing the environment and the sustainability of the society as a whole. These decisions will affect the way corporations and government work, and the shape of the business environment. Changes in consumer behavior will affect how corporations and government will deliver their goods and services. The goal is to raise the level of debate on climate change and the environment, and promote an understanding of what government officials at the federal, state and municipal level are trying to say and do. This audio conference looks at the concepts behind the trendy buzzwords, and examines both the social and business case for 'going green'.
Tuesday, August 24, 2010
Budgeting for Translations
is being presented by Jason Heaton, of ForeignExchange Translations and airs on Wednesday, September 29th, 2010. For more details or to register, please visit our site at www.fxconferences.com
Do you struggle with budgeting for translations? You’re not alone. Translation used to be an afterthought, a line item tacked onto the bottom of a budget. My, how things have changed... With the flattening world comes an increased need for localized, translated product documentation. In a tough global economy, companies’ upper management are sharpening pencils and paying more attention to translation costs. This means more pressure to find ways to accurately forecast, and budget for, translations.
The trouble is, translation work has many variables that conspire to make budgeting seem like something akin to fortune telling. Project schedules, different language needs and rates, document types and translation memory leveraging are only some of these variables. The key to increasing accuracy in translation budgeting lies in the ability to minimize or lock down the variability to a predictable level.
This audio conference provides an overview of the variables that impact translation budgeting. It offers an insider’s view of how projects are priced at a translation agency and how you can maximize efficiency and work with your providers to keep costs lower and more predictable. Finally, the discussion covers concrete tips on how to create ballpark budgets for your translation projects and extrapolate for quarterly and annual numbers.
Do you struggle with budgeting for translations? You’re not alone. Translation used to be an afterthought, a line item tacked onto the bottom of a budget. My, how things have changed... With the flattening world comes an increased need for localized, translated product documentation. In a tough global economy, companies’ upper management are sharpening pencils and paying more attention to translation costs. This means more pressure to find ways to accurately forecast, and budget for, translations.
The trouble is, translation work has many variables that conspire to make budgeting seem like something akin to fortune telling. Project schedules, different language needs and rates, document types and translation memory leveraging are only some of these variables. The key to increasing accuracy in translation budgeting lies in the ability to minimize or lock down the variability to a predictable level.
This audio conference provides an overview of the variables that impact translation budgeting. It offers an insider’s view of how projects are priced at a translation agency and how you can maximize efficiency and work with your providers to keep costs lower and more predictable. Finally, the discussion covers concrete tips on how to create ballpark budgets for your translation projects and extrapolate for quarterly and annual numbers.
Monday, August 23, 2010
CGMP Guidance for Phase 1 Clinical Supplies
is being presented by Marion Weinreb, President, of Marion Weinreb & Associates, Inc. and airs on Tuesday, October 5th, 2010. For more details or to register, please visit our site at www.fxconferences.com
The new FDA guidance document for Phase 1 clinical supplies is significant because it will enable companies (large and small) to move faster through their clinical manufacturing process, while not being bogged down with complying with all aspects of 21CFR Part 211. FDA realized that the CGMPs should not have been enforced for Phase 1 clinical supplies. This guidance document focuses primarily on controls that prevent adulteration and misbranding of the Phase 1 clinical supplies. It allows flexibility in implementing the controls needed to achieve those goals. In this audio conference, our speaker reviews the guidelines, identifies the types of SOPs and controls that are needed, and identifies for the virtual company, what types of SOPs are needed to deal with vendor relationships.
The new FDA guidance document for Phase 1 clinical supplies is significant because it will enable companies (large and small) to move faster through their clinical manufacturing process, while not being bogged down with complying with all aspects of 21CFR Part 211. FDA realized that the CGMPs should not have been enforced for Phase 1 clinical supplies. This guidance document focuses primarily on controls that prevent adulteration and misbranding of the Phase 1 clinical supplies. It allows flexibility in implementing the controls needed to achieve those goals. In this audio conference, our speaker reviews the guidelines, identifies the types of SOPs and controls that are needed, and identifies for the virtual company, what types of SOPs are needed to deal with vendor relationships.
Subscribe to:
Posts (Atom)